Indications and recommendations for the use of recombinant human growth hormone in adult short bowel syndrome patients dependent on parenteral nutrition

Journal of Clinical Gastroenterology

Volumn 40, Issue SUPPL. 2, 2006, Pages

  Steiger, Ezra ^a   DiBaise, John K ^b   Messing, Bernard ^c   Matarese, Laura E ^d   Blethen, Sandra ^e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

^c HÔPITAL LARIBOISIÈRE   (France)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^e EMD SERONO INC   (United States)

Author keywords

Management; Recombinant growth hormone; Short bowel syndrome; Trophic factors

Indexed keywords

DIURETIC AGENT; GLUCAGON LIKE PEPTIDE 2; GLUTAMINE; HORMONE ANALOG; HUMAN GROWTH HORMONE; SOMATREM; TEDUGLUTIDE; UNCLASSIFIED DRUG; RECOMBINANT PROTEIN;

ABDOMINAL PAIN; ALGORITHM; ARTHRALGIA; CARDIOVASCULAR DISEASE; CARPAL TUNNEL SYNDROME; CLINICAL TRIAL; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG POTENTIATION; EDEMA; FATIGUE; GASTROINTESTINAL DISEASE; GLUCOSE INTOLERANCE; GYNECOMASTIA; HAND; HAND PARESTHESIA; HEADACHE; HUMAN; INTESTINE ADAPTATION; JOINT STIFFNESS; LEG EDEMA; MUSCLE STIFFNESS; MUSCULOSKELETAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PAIN; PARENTERAL NUTRITION; PATIENT SELECTION; PERIPHERAL EDEMA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SHORT BOWEL SYNDROME; SLEEP DISORDER; SWELLING; TACHYCARDIA; TREATMENT DURATION; ADULT; PRACTICE GUIDELINE; TREATMENT OUTCOME;

ADULT; HUMAN GROWTH HORMONE; HUMANS; PARENTERAL NUTRITION; PRACTICE GUIDELINES; RECOMBINANT PROTEINS; SHORT BOWEL SYNDROME; TREATMENT OUTCOME;

EID: 33745297406     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000212680.52290.02     Document Type: Review

References (67)

1. Buchman AL, Scolapio J, Fryer J. AGA technical review on short bowel syndrome and intestinal transplantation. Gastroenterology. 2003;124:1111-1134.
2. Crenn P, Morin MC, Joly F, et al. Net digestive absorption and adaptive hyperphagia in adult short bowel patients. Gut. 2004;53:1279-1286.
3. Messing B, Crenn P, Beau P, et al. Long-term survival and parenteral nutrition dependence in adult patients with the short bowel syndrome. Gastroenterology. 1999;117:1043-1050.
4. Howard L, Ament M, Fleming CR, et al. Current use and clinical outcome of home parenteral and enteral nutrition therapies in the United States. Gastroenterology. 1995;109:355-365.
5. Tokars JI, Cookson ST, McArthur MA, et al. Prospective evaluation of risk factors for bloodstream infection in patients receiving home infusion therapy. Ann Intern Med. 1999;131:340-347.
6. Cavicchi M, Beau P, Crenn P, et al. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med. 2000;132:525-532.
7. DiBaise JK, Matarese LE, Messing B, et al. Strategies for weaning parenteral nutrition in adult patients with short bowel syndrome. J Clin Gastroenterol. 2006;40(Suppl. 2):S94-S98.
8. Matarese LE, Steiger E. Dietary management in adult patients with short bowel syndrome. J Clin Gastroenterol. 2006;40(Suppl. 2):S85-S93.
9. Byrne TA, Veglia LM, Camelio M, et al. Beyond the prescription: optimizing the diet of patients with short bowel syndrome. Nutr Clin Prac. 2000;15:306-311.
10. American Gastroenterological Association medical position statement: short bowel syndrome and intestinal transplantation. Gastroenterology. 2003;124:1105-1110.
11. Jeppesen PB, Langholz E, Mortensen PB. Quality of life in patients receiving home parenteral nutrition. Gut. 1999;44:844-852.
12. Rubin DC. Nutrient regulation of intestinal growth and adaptation: role of glucagon-like peptide 2 and the enteroendocrine cell. Gastroenterology. 1999;117:261-263.
13. Nightingale J. Short bowel, short answer? Gut. 1999;45:478-479.
14. Drucker DJ, Erlich P, Asa SL, et al. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA. 1996;93:7911-7916.
15. Scott RB, Kirk D, MacNaughton WK, et al. GLP-2 augments the adaptive response to massive intestinal resection in rat. Am J Physiol. 1998;275:G911-G921.
16. Thulesen J, Hartmann B, Kissow H, et al. Intestinal growth adaptation and glucagon-like peptide 2 in rats with ileal-jejunal transposition or small bowel resection. Dig Dis Sci. 2001;46:379-388.
17. Jeppesen PB, Hartmann B, Thulesen J, et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology. 2001;120:806-815.
18. Jeppesen PB, Sanguinetti EL, Buchman A, et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut. 2005;54:1224-1231.
19. Hart MH, Phares CK, Erdman SH, et al. Augmentation of postresection mucosal hyperplasia by plerocercoid growth factor (PGF): Analog of human growth hormone. Dig Dis Sci. 1987;32:1275-1280.
20. Shulman DI, Hu CS, Duckett G, et al. Effects of short-term growth hormone therapy in rats undergoing 75% small intestinal resection. J Pediatr Gastroenterol Nutr. 1992;14:3-11.
21. Gu Y, Wu ZH, Xie JX, et al. Effects of growth hormone (rhGH) and glutamine supplemented parenteral nutrition on intestinal adaptation in short bowel rats. Clin Nutr. 2001;20:159-166.
22. Christensen H, Jorgensen PH, Oxlund H, et al. Growth hormone increases the mass, the collagenous proteins, and the strength of rat colon. Scand J Gastroenterol. 1990;25:1137-1143.
23. Mainoya JR. Effects of bovine growth hormone, human placental lactogen and ovine prolactin on intestinal fluid and ion transport in the rat. Endocrinology. 1975;96:1165-1170.
24. Mainoya JR. Influence of ovine growth hormone on water and NaCl absorption by the rat proximal jejunum and distal ileum. Comp Biochem Physiol A. 1982;71:477-479.
25. Inoue Y, Copeland EM, Souba WW. Growth hormone enhances amino acid uptake by the human small intestine. Ann Surg. 1994;219:715-722; discussion 722-724.
26. Challacombe DN, Wheeler EE. The trophic action of human growth hormone on human duodenal mucosa cultured in vitro. J Pediatr Gastroenterol Nutr. 1995;21:50-53.
27. Messing B, Blethen S, DiBaise JK, et al. Treatment of adult short bowel syndrome with recombinant human growth hormone: a review of clinical studies. J Clin Gastroenterol. 2006;40(Suppl. 2):S75-S84.
28. Seguy D, Vahedi K, Kapel N, et al. Low-dose growth hormone in adult home parenteral nutrition-dependent short bowel syndrome patients: a positive study. Gastroenterology. 2003;124:293-302.
29. Byrne TA, Wilmore DW, Iyer K, et al. Growth hormone and an optimal diet with or without glutamine reduces parenteral nutrition in patients with short bowel syndrome. Ann Surg. 2005;242:655-661.
30. Byrne TA, Morrissey TB, Nattakom TV, et al. Growth hormone, glutamine, and a modified diet enhance nutrient absorption in patients with severe short bowel syndrome. JPEN J Parenter Enteral Nutr. 1995;19:296-302.
31. Byrne TA, Persinger RL, Young LS, et al. A new treatment for patients with short-bowel syndrome. Growth hormone, glutamine, and a modified diet. Ann Surg. 1995;222:243-254; discussion 254-255.
32. Byrne TA, Cox S, Karimbakas M, et al. Bowel rehabilitation: an alternative to long-term parenteral nutrition and intestinal transplantation for some patients with short bowel syndrome. Transplant Proc. 2002;34:887-890.
33. Wu GH, Wu ZH, Wu ZG. Effects of bowel rehabilitation and combined trophic therapy on intestinal adaptation in short bowel patients. World J Gastroenterol. 2003;9:2601-2604.
34. Weiming Z, Ning L, Jian'an R, et al. Rehabilitation therapy for short bowel syndrome. Chin Med J (Engl). 2002;115:776-778.
35. Wilmore DW, Lacey JM, Soultanakis RP, et al. Factors predicting a successful outcome after pharmacologic bowel compensation. Ann Surg. 1997;226:288-292; discussion, 292-293.
36. Weiming Z, Ning L, Jieshou L. Effect of recombinant human growth hormone and enteral nutrition on short bowel syndrome. JPEN J Parenter Enteral Nutr. 2004;28:377-381.
37. Ellegard L, Bosaeus I, Nordgren S, et al. Low-dose recombinant human growth hormone increases body weight and lean body mass in patients with short bowel syndrome. Ann Surg. 1997;225:88-96.
38. Zhu W, Li N, Ren J, et al. Rehabilitation therapy for short bowel syndrome. Chin Med J (Engl). 2002;115:776-778.
39. O'Dwyer ST, Smith RJ, Hwang TL, et al. Maintenance of small bowel mucosa with glutamine-enriched parenteral nutrition. JPEN J Parenter Enteral Nutr. 1989;13:579-585.
40. van der Hulst RR, van Kreel BK, von Meyenfeldt MF, et al. Glutamine and the preservation of gut integrity. Lancet. 1993;341:1363-1365.
41. Rhoads JM, Argenzio RA, Chen W, et al. L-glutamine stimulates intestinal cell proliferation and activates mitogen-activated protein kinases. Am J Physiol. 1997;272:G943-G953.
42. Ziegler TR, Mantell MP, Chow JC, et al. Gut adaptation and the insulin-like growth factor system: regulation by glutamine and IGF-I administration. Am J Physiol. 1996;271:G866-G875.
43. Scolapio JS, Camilleri M, Fleming CR, et al. Effect of growth hormone, glutamine, and diet on adaptation in short-bowel syndrome: a randomized, controlled study. Gastroenterology. 1997;113:1074-1081.
44. Scolapio JS. Effect of growth hormone, glutamine, and diet on body composition in short bowel syndrome: a randomized, controlled study. JPEN J Parenter Enteral Nutr. 1999;23:309-312; discussion: 312-313.
45. Jeppesen PB, Szkudlarek J, Hoy CE, et al. Effect of high-dose growth hormone and glutamine on body composition, urine creatinine excretion, fatty acid absorption, and essential fatty acids status in short bowel patients: a randomized, double-blind, crossover, placebo-controlled study. Scand J Gastroenterol. 2001;36:48-54.
46. Szkudlarek J, Jeppesen PB, Mortensen PB. Effect of high dose growth hormone with glutamine and no change in diet on intestinal absorption in short bowel patients: a randomised, double blind, crossover, placebo controlled study. Gut. 2000;47:199-205.
47. Nightingale JM, Lennard-Jones JE, Gertner DJ, et al. Colonic preservation reduces need for parenteral therapy, increases incidence of renal stones, but does not change high prevalence of gall stones in patients with a short bowel. Gut. 1992;33:1493-1497.
48. Matarese LE, Seidner DL, Steiger E. Growth hormone, glutamine, and modified diet for intestinal adaptation. J Am Diet Assoc. 2004;104:1265-1272.
49. Harris M, Hofman PL, Cutfield WS. Growth hormone treatment in children: review of safety and efficacy. Paediatr Drugs. 2004;6:93-106.
50. Blethen SL, Allen DB, Graves D, et al. Safety of recombinant deoxyribonucleic acid-derived growth hormone: the national cooperative growth study experience. J Clin Endocrinol Metab. 1996;81:1704-1710.
51. Chu LW, Lam KS, Tam SC, et al. A randomized controlled trial of low-dose recombinant human growth hormone in the treatment of malnourished elderly medical patients. J Clin Endocrinol Metab. 2001;86:1913-1920.
52. Serono, Inc. Zorbtive [Somatropin (rDNA Origin) for Injection] Package Insert. Geneva, Switzerland, Serono; 2004.
53. Mills JL, Schonberger LB, Wysowski DK, et al. Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients. J Pediatr. 2004;144:430-436.
54. Giovannucci E, Pollak M. Risk of cancer after growth-hormone treatment. Lancet. 2002;360:268-269.
55. Swerdlow AJ, Higgins CD, Adlard P, et al. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-1985: a cohort study. Lancet. 2002;360:273-277.
56. Greer RM, Quirk P, Cleghorn GJ, et al. Growth hormone resistance and somatomedins in children with end-stage liver disease awaiting transplantation. J Pediatr Gastroenterol Nutr. 1998;27:148-154.
57. Rodeck B, Kardorff R, Melter M, et al. Improvement of growth after growth hormone treatment in children who undergo liver transplantation. J Pediatr Gastroenterol Nutr. 2000;31:286-290.
58. Sarna S, Sipila I, Ronnholm K, et al. Recombinant human growth hormone improves growth in children receiving glucocorticoid treatment after liver transplantation. J Clin Endocrinol Metab. 1996;81:1476-1482.
59. Wuhl E, Schaefer F. Effects of growth hormone in patients with chronic renal failure: experience in children and adults. Horm Res. 2002;58(Suppl. 3):35-38.
60. Jeffcoate W. Growth hormone therapy and its relationship to insulin resistance, glucose intolerance and diabetes mellitus: A review of recent evidence. Drug Safety. 2002;25:199-212.
61. Serono, Inc. Serostim [Somatropin (rDNA Origin) for Injection] Package Insert. Geneva, Switzerland, Serono; 2004.
62. Schambelan M, Mulligan K, Grunfeld C, et al. Recombinant human growth hormone in patients with HIV-associated wasting: a randomized, placebo-controlled trial. Serostim Study Group. Ann Intern Med. 1996;125:873-882.
63. Serono, Inc. Data on file. Geneva, Switzerland, Serono; 2003.
64. Pharmacia. Genotropin [Somatropin (rDNA Origin) for Injection] Package Insert. Quebec, Canada, Pharmacia; 2004.
65. Eli Lilly. Humatrope [Somatropin (rDNA Origin) for Injection] Package Insert. Indianapolis, Indiana, Eli Lilly, 2005.
66. Genentech. Protropin [Somatrem for Injection] Package Insert. South San Francisco, California, Genentech, 2001.
67. Jeppesen PB. Clinical significance of GLP-2 in short-bowel syndrome. J Nutr. 2003;133:3721-3724.